Oral complications in the treatment of cancer patients

Oral Diseases

Volumn 17, Issue 6, 2011, Pages 550-559

  Mosel, D D ^a   Bauer, R L ^a   Lynch, D P ^b   Hwang, S T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MARQUETTE UNIVERSITY SCHOOL OF DENTISTRY   (United States)

Author keywords

Craniofacial; Oncology

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMSACRINE; ANTIFUNGAL AGENT; BLEOMYCIN; CASPOFUNGIN; CYTARABINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUCONAZOLE; FLUOROURACIL; ITRACONAZOLE; METHOTREXATE; MITOXANTRONE; PALIFERMIN; POSACONAZOLE; SPORONOX; THIOGUANINE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANDIDA ALBICANS; CANDIDIASIS; CRYOTHERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HEAD AND NECK CANCER; HUMAN; MOUTH DISEASE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; THRUSH; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CANDIDIASIS, ORAL; DYSGEUSIA; HEAD AND NECK NEOPLASMS; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MOUTH DISEASES; OPPORTUNISTIC INFECTIONS; RADIATION INJURIES; STOMATITIS;

EID: 79960700200     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01788.x     Document Type: Review

References (71)

1. Arduino PG, Porter SR (2006). Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis 12: 254-270.
2. Beutner KR (1995). Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 28: 281-290.
3. Bhandarkar SS, MacKelfresh J, Fried L, Arbiser JL (2008). Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol 58: 711-712.
4. Blomgren J, Back H (1996). Oral hairy leukoplakia in a patient with multiple myeloma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82: 408-410.
5. von Bultzingslowen I, Brennan MT, Spijkervet FK et al (2006). Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 14: 519-527.
6. de la Camara R, Jarque I, Sanz MA et al (2010). Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 45: 925-932.
7. Chan A, Ignoffo RJ (2005). Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract 11: 139-143.
8. Chan S, Gerson B, Subramaniam S (1998). The role of copper, molybdenum, selenium, and zinc in nutrition and health. Clin Lab Med 18: 673-685.
9. Cheng KK (2007). Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J Clin Nurs 16: 2114-2121.
10. Chilukuri S, Rosen T (2003). Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21: 311-320.
11. Cho HH, Kim SH, Seo SH et al (2010). Oral hairy leukoplakia which occurred as a presenting sign of acute myeloid leukemia in a child. Ann Dermatol 22: 73-76.
12. Collins CD, Ellis JJ, Kaul DR (2008). Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 65: 2237-2243.
13. Cowart B (2011). Taste dysfunction: a practical guide for oral medicine. Oral Dis 17: 2-6.
14. Diaz-Arnold AM, Marek CA (2002). The impact of saliva on patient care: a literature review. J Prosthet Dent 88: 337-343.
15. Doerr TD, Prasad AS, Marks SC et al (1997). Zinc deficiency in head and neck cancer patients. J Am Coll Nutr 16: 418-422.
16. Duvic M, Talpur R, Ni X et al (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39.
17. Elad S, Zadik Y, Hewson I et al. (2010). A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Support Care Cancer 18: 993-1006.
18. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003). The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98: 1531-1539.
19. Elting LS, Keefe DM, Sonis ST et al. (2008). Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113: 2704-2713.
20. Fink M (2010). Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol [Epub ahead of print].
21. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009). Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 1: CD006706.
22. Halyard MY (2009). Taste and smell alterations in cancer patients - real problems with few solutions. J Support Oncol 7: 68-69.
23. Halyard MY, Jatoi A, Sloan JA et al (2007). Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 67: 1318-1322.
24. Hong CH, Napenas JJ, Hodgson BD et al (2010). A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18: 1007-1021.
25. Hovan AJ, Williams PM, Stevenson-Moore P et al (2010). A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18: 1081-1087.
26. Keefe DM, Schubert MM, Elting LS et al (2007). Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109: 820-831.
27. Komaki R, Lee JS, Milas L et al (2004). Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58: 1369-1377.
28. Kostler WJ, Hejna M, Wenzel C, Zielinski CC (2001). Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin 51: 290-315.
29. Lalla RV, Sonis ST, Peterson DE (2008). Management of oral mucositis in patients who have cancer. Dent Clin North Am. 52: 61-77, viii.
30. Lalla RV, Latortue MC, Hong CH et al. (2010). A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18: 985-992.
31. Martin MV (2000). The use of fluconazole and itraconazole in the treatment of candida albicans infections: a review. J Antimicrob Chemother 45: 555.
32. Meis JF, Verweij PE (2001). Current management of fungal infections. Drugs 61(Suppl. 1): 13-25.
33. Miller M, Kearney N (2001). Oral care for patients with cancer: a review of the literature. Cancer Nurs 24: 241-254.
34. Moura MD, Guimaraes TR, Fonseca LM, de Almeida Pordeus I, Mesquita RA (2007). A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 64-71.
35. Moura MD, Haddad JP, Senna MI, Ferreira e Ferreira E, Mesquita RA (2010). A new topical treatment protocol for oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110: 611-617.
36. Nicolatou O, Nikolatos G, Fisfis M et al (1999). Oral hairy leukoplakia in a patient with acute lymphocytic leukemia. Oral Dis 5: 76-79.
37. Noe JE (2009). L-glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integr Cancer Ther 8: 409-415.
38. Ohrn KE, Wahlin YB, Sjoden PO (2001). Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9: 247-257.
39. Pappas PG, Kauffman CA, Andes D et al (2009). Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 48: 503-535.
40. Paris F, Fuks Z, Kang A et al (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297.
41. Pereira CM, Souza CA, Correa ME (2010). Herpetic geometric glossitis: acyclovir resistant case in a patient with acute myelogenous leukemia. Indian J Pathol Microbiol 53: 133-134.
42. Peterson DE, Jones JB, Petit RG 2nd (2007). Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109: 322-331.
43. Pico JL, Avila-Garavito A, Naccache P (1998). Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3: 446-451.
44. Piperi E, Omlie J, Koutlas IG, Pambuccian S (2010). Oral hairy leukoplakia in HIV-negative patients: report of 10 cases. Int J Surg Pathol 18: 177-183.
45. Rautemaa R, Lauhio A, Cullinan MP, Seymour GJ (2007). Oral infections and systemic disease - an emerging problem in medicine. Clin Microbiol Infect 13: 1041-1047.
46. Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME (2005a). Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27: 659-668.
47. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME (2005b). Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23: 1431-1438.
48. Ravasco P, Monteiro Grillo I, Camilo M (2007). Cancer wasting and quality of life react to early individualized nutritional counselling!. Clin Nutr 26: 7-15.
49. Reusser P (2002). Management of viral infections in immunocompromised cancer patients. Swiss Med Wkly 132: 374-378.
50. Schmidt E, Thoennissen NH, Rudat A et al (2008). Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol 19: 1644-1649.
51. Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R (2008). Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther 30: 964-973.
52. Scully C, Sonis S, Diz PD (2006). Oral mucositis. Oral Dis 12: 229-241.
53. Silva GB, Mendonca EF, Bariani C, Antunes HS, Silva MA (2010). The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg 29: 27-31.
54. Sohn HS, Lee TJ, Kim J, Kim D (2009). Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 31: 1105-1115; discussion 1066-1068.
55. Sonis ST (2007). Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5: 3-11.
56. Sonis ST (2010). New thoughts on the initiation of mucositis. Oral Dis 16: 597-600.
57. Sonis ST, Fey EG (2002). Oral complications of cancer therapy. Oncology (Williston Park) 16: 680-686; discussion 686, 691-692, 695.
58. Spielberger R, Stiff P, Bensinger W et al (2004). Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351: 2590-2598.
59. Stam WB, O'Sullivan AK, Rijnders B et al (2008). Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 81: 467-474.
60. Sukhotnik I, Mogilner JG, Karry R et al (2009a). Effect of oral glutamine on enterocyte turnover during methotrexate-induced mucositis in rats. Digestion 79: 5-13.
61. Sukhotnik I, Mogilner JG, Shteinberg D et al (2009b). Leptin accelerates enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. Cancer Biol Ther 8: 899-906.
62. Syrjanen S, Laine P, Niemela M, Happonen RP (1989). Oral hairy leukoplakia is not a specific sign of HIV-infection but related to immunosuppression in general. J Oral Pathol Med 18: 28-31.
63. Vadhan-Raj S, Trent J, Patel S et al (2010). Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 153: 358-367.
64. Vazquez JA (2003). Invasive oesophageal candidiasis: current and developing treatment options. Drugs 63: 971-989.
65. Walling DM, Flaitz CM, Nichols CM (2003). Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J Infect Dis 188: 883-890.
66. Watkins B, Pouliot K, Fey E, Tuthill C, Sonis S (2010). Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis 16: 655-660.
67. Wearing HJ, Sherratt JA (2000). Keratinocyte growth factor signalling: a mathematical model of dermal-epidermal interaction in epidermal wound healing. Math Biosci 165: 41-62.
68. Whittaker SJ, Demierre MF, Kim EJ et al (2010). Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28: 4485-4491.
69. Worthington HV, Clarkson JE, Khalid T, Meyer S, McCabe M (2010). Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2: CD001972.
70. Yamashita H, Nakagawa K, Nakamura N et al (2006). Relation between acute and late irradiation impairment of four basic tastes and irradiated tongue volume in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 66: 1422-1429.
71. Zackheim HS, Kashani-Sabet M, McMillan A (2003). Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49: 873-878.